Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Основные генетические и биологические маркеры псориаза
Основные генетические и биологические маркеры псориаза
Мельниченко О.О., Денисова Е.В., Жукова О.В., Потекаев Н.Н. Основные генетические и биологические маркеры псориаза. Consilium Medicum. 2021; 23 (8): 672–675. DOI: 10.26442/20751753.2021.8.201188
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обоснование. Псориаз – это хроническое воспалительное аутоиммунное заболевание, характеризующееся чрезмерно аберрантной гиперпролиферацией кератиноцитов. Патогенез псориаза сложен, и точный механизм, несмотря на многочисленные исследования, до сих пор остается неясным. Сложные генетические связи играют важную роль в патогенезе этого дерматологического заболевания. В развитии псориаза задействовано большое количество генов, также ассоциированных с другими заболеваниями. Широкий спектр наблюдаемых у пациентов с псориазом коморбидных состояний зачастую весьма затрудняет терапию дерматоза. Понимание роли некоторых генов в патогенезе псориатического процесса позволит разработать более эффективное целевое лечение, направленное на блокирование соответствующих воспалительных сигнальных путей и молекул.
Цель. Проанализировать и систематизировать основные генетические и биологические маркеры псориаза.
Материалы и методы. В исследование включены исследовательские статьи, посвященные генетическому анализу псориаза. Использовались реферативные базы ResNet, PubMed и eLibrary.
Результаты и обсуждение. В результате проведенного детального анализа литературных источников, посвященных псориатической болезни, определен круг основных генетических и биологических маркеров. Уделено внимание роли и влиянию однонуклеотидных полиморфизмов, которые позволяют установить четкую ассоциацию ряда генов, задействованных в развитии псориаза. Отдельно рассматривались гены с измененной экспрессией при псориатическом процессе.
Заключение. Выявленные биомаркеры могут применяться в направленной биологической терапии псориаза с использованием биологических модуляторов, которые блокируют передачу сигналов.
Ключевые слова: псориаз, генетические маркеры, биомаркеры
Aim. To analyze and systematize the basic genetic and biological markers of psoriasis.
Materials and methods. The study included research articles on the genetic analysis of psoriasis. The ResNet, PubMed and eLibrary databases were used.
Results and discussion. Basic genetic and biological markers were identified by analysis of literature sources devoted to psoriasis. Attention is paid to the role and effects of single nucleotide polymorphisms, which make it possible to establish a clear association of a number of genes involved in the development of psoriasis. Genes with altered expression in the psoriatic process were considered separately.
Conclusion. The identified biomarkers can be used in targeted biological therapy of psoriasis using biological modulators that block signaling.
Keywords: psoriasis, genetic markers, biomarkers
Цель. Проанализировать и систематизировать основные генетические и биологические маркеры псориаза.
Материалы и методы. В исследование включены исследовательские статьи, посвященные генетическому анализу псориаза. Использовались реферативные базы ResNet, PubMed и eLibrary.
Результаты и обсуждение. В результате проведенного детального анализа литературных источников, посвященных псориатической болезни, определен круг основных генетических и биологических маркеров. Уделено внимание роли и влиянию однонуклеотидных полиморфизмов, которые позволяют установить четкую ассоциацию ряда генов, задействованных в развитии псориаза. Отдельно рассматривались гены с измененной экспрессией при псориатическом процессе.
Заключение. Выявленные биомаркеры могут применяться в направленной биологической терапии псориаза с использованием биологических модуляторов, которые блокируют передачу сигналов.
Ключевые слова: псориаз, генетические маркеры, биомаркеры
________________________________________________
Aim. To analyze and systematize the basic genetic and biological markers of psoriasis.
Materials and methods. The study included research articles on the genetic analysis of psoriasis. The ResNet, PubMed and eLibrary databases were used.
Results and discussion. Basic genetic and biological markers were identified by analysis of literature sources devoted to psoriasis. Attention is paid to the role and effects of single nucleotide polymorphisms, which make it possible to establish a clear association of a number of genes involved in the development of psoriasis. Genes with altered expression in the psoriatic process were considered separately.
Conclusion. The identified biomarkers can be used in targeted biological therapy of psoriasis using biological modulators that block signaling.
Keywords: psoriasis, genetic markers, biomarkers
Полный текст
Список литературы
1. Seldin MF. The Genetics of Human Autoimmune Disease: A Perspective on Progress in the Field and Future Directions. J Autoimmun. 2015;64:1-12. DOI:10.1016/j.jaut.2015.08.015
2. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449-53. PMID: 18609743
3. Nesterova AP, Klimov EA, Zharkova M, et al. Diseases of the skin and subcutaneous tissue. In Disease Pathways. Elsevier, 2020; p. 493-532. DOI:10.1016/B978-0-12-817086-1.00011-7
4. Nesterova AP, Yuryev A, Klimov EA, et al. Disease Pathways: An atlas of human disease signaling pathways. 1st ed. Elsevier: Waltham, 2019. DOI:10.1016/C2018-0-00586-1
5. Sobolev VV, Mezentsev AV, Ziganshin RH, et al. LC-MS/MS Analysis of Lesional and Normally Looking Psoriatic Skin Reveals Significant Changes in Protein Metabolism and RNA Processing. PLoS One. 2021;16:e0240956. DOI:10.1371/journal.pone.0240956
6. Farber EM, Nall L. The Natural History of Psoriasis in 5,600 Patients. Dermatology. 1974;148:1-18. DOI:10.1159/000251595
7. Allione A, Marcon F, Fiorito G, et al. Novel Epigenetic Changes Unveiled by Monozygotic Twins Discordant for Smoking Habits. PloS One. 2015;10:e0128265. DOI:10.1371/journal.pone.0128265
8. Park J-H, Wacholder S, Gail MH, et al. Estimation of Effect Size Distribution from Genome-Wide Association Studies and Implications for Future Discoveries. Nat Genet. 2010;42:570-5. DOI:10.1038/ng.610
9. Nair RP, Stuart PE, Nistor I, et al. Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene. Am J Hum Genet. 2006;78:827-51. DOI:10.1086/503821
10. Hız MM, Kılıç S, Oymak S, et al. Psoriasis and Genetics. IntechOpen: Rijeka, 2017. DOI:10.5772/intechopen.68344
11. De Cid R, Riveira-Munoz E, Zeeuwen PLJM, et al. Deletion of the Late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009;41:211-5. DOI:10.1038/ng.313
12. Coto-Segura P, Coto E, Mas-Vidal A, et al. Influence of Endothelial Nitric Oxide Synthase Polymorphisms in Psoriasis Risk. Arch Dermatol Res. 2011;303:445-9.
DOI:10.1007/s00403-011-1129-9
13. Fu L, Zhao Y, Lu J, et al. Functional Single Nucleotide Polymorphism-1026C/A of Inducible Nitric Oxide Synthase Gene with Increased YY1-Binding Affinity Is Associated with Hypertension in a Chinese Han Population. J Hypertens. 2009;27:991-1000. DOI:10.1097/hjh.0b013e3283294bec
14. Klimov EА, Tretiakov AV, Gapanovich ES, et al. Evaluation of the role of polymorphic variants of no-synthases genes of in pathogenesis of psoriasis. Mol Meditsina Mol Med. 2018;16. DOI:10.29296/24999490-2018-04-11
15. Klimov E, Tretiakov A, Gapanovich E, et al. Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis. J Adv Med Med Res. 2018;26:1-6. DOI:10.9734/JAMMR/2018/41039
16. Sobolev V, Sakaniya L, Tretiakov A, et al. Association of GA Genotype of SNP Rs4680 in COMT Gene with Psoriasis. Arch Dermatol Res. 2019;311:309-15. DOI:10.1007/s00403-019-01904-1
17. Sakaniya LR, Tretiakov AV, Shevtsova AA, et al. DBH gene polymorphism in psoriasis patients. Mol Meditsina Mol Med. 2019;17. DOI:10.29296/24999490-2019-04-09
18. Klimov E, Tretiakov A, Rudko O, et al. Psychodermatology: a molecular link between psoriasis and anxiety disorder. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27. DOI:10.15570/actaapa.2018.38
19. Sobolev V, Klimov E, Tretiakov A, et al. 218 polymorphism of dopamine related genes in the light of psychodermatology: association with psoriasis. J Invest Dermatol. 2017;137:S230. DOI:10.1016/j.jid.2017.07.215
20. Соболев В.В., Третьяков А.В., Рудько О.И., и др. Психодерматология: молекулярная общность псориаза и тревожного расстройства. Эффективная фармакотерапия. 2017;15:10-5 [Sobolev VV, Tret'iakov AV, Rud'ko OI, et al. Psikhodermatologiia: molekuliarnaia obshchnost' psoriaza i trevozhnogo rasstroistva. Effektivnaia farmakoterapiia. 2017;15:10-5 (in Russian)].
21. Данилин И.Е., Невозинска З.А., Третьяков А.В., и др. Анализ взаимосвязи кожных и эмоциональных расстройств у больных псориазом. Вестник неврологии, психиатрии и нейрохирургии. 2020;11 [Danilin IE, Niewozinska ZA, Tretiakov AV, et al. Analysis of the relationship between skin and emotional disorders in patients with psoriasis. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;11 (in Russian)]. DOI: 10.33920/med-01-2011-02
22. Nair RP, Duffin KC, Helms C, et al. Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-KappaB Pathways. Nat Genet. 2009;41:199-204. DOI:10.1038/ng.311
23. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE. 2011;6:e17160. DOI: 10.1371/journal.pone.0017160
24. Соболев В.В., Третьяков А.В., Шевцова А.А., и др. Связь между однонуклеотидной заменой T>C в гене MIR22 и развитием псориаза. Эффективная фармакотерапия. 2018;34:18-20 [Sobolev VV, Tret'iakov AV, Shevtsova AA, et al, Sviaz' mezhdu odnonukleotidnoi zamenoi T>C v gene MIR22 i razvitiem psoriaza. Effektivnaia farmakoterapiia. 2018;34:18-20 (in Russian)].
25. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the Interleukin-17 Isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-24.
DOI:10.1111/j.1365-2133.2008.08902.x
26. Sobolev VV, Sautin ME, Piruzian ES, et al. IL-17 gene expression levels in atherosclerosis and psoriasis. Prime. 2015;5:34-8. Available at: https://www.prime-journal.com/il-17-gene-expression-levels-in-atherosclerosis-and-psoriasis/ Accessed: 13.08.2021.
27. Isailovic N, Daigo K, Mantovan A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1-11. DOI:10.1016/j.jaut.2015.04.006
28. Lai Y, Li D, Li C, et al. The Antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity. 2012;37:74-84. DOI:10.1016/j.immuni.2012.04.010
29. Соболев В.В., Денисова Е.В., Корсунская И.М. Изменение экспрессии гена S100А8 под воздействием лазерного излучения низкой интенсивности у больных псориазом. Эффективная фармакотерапия. 2021;17:14-6 [Sobolev VV, Denisova EV, Korsunskaia IM. Izmenenie ekspressii gena S100A8 pod vozdeistviem lazernogo izlucheniia nizkoi intensivnosti u bol'nykh psoriazom. Effektivnaia farmakoterapiia. 2021;17:14-6 (in Russian)]. DOI:10.33978/2307-3586-2021-17-1-14-16
30. Ильина С.А., Золотаренко А.Д., Пирузян А.Л., и др. Экспрессия генов S100A8 и S100A9 в пораженной псориатическим процессом коже. Технологии живых систем. 2010;7:45-51 [Il'ina SA, Zolotarenko AD, Piruzian AL, et al. Ekspressiia genov S100A8 i S100A9 v porazhennoi psoriaticheskim protsessom kozhe. Tekhnologii zhivykh sistem. 2010;7:45-51 (in Russian)].
31. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C Regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-66. DOI:10.1038/ni.2156
32. Kanda N, Koike S, Watanabe S. IL-17 Suppresses TNF-Alpha-Induced CCL27 Production through Induction of COX-2 in Human Keratinocytes. J Allergy Clin Immunol. 2005;116:1144-50. DOI:10.1016/j.jaci.2005.08.014
33. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-90. DOI:10.1086/511051
34. Johnson-Huang LM, Suárez-Fariñas M, Pierson KC, et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol. 2012;132:1177-87. DOI:10.1038/jid.2011.458
35. Соболев В.В., Денисова Е.В., Корсунская И.М. Изменение экспрессии гена STAT3 при лечении псориаза. Медицинский совет. 2020;12:71-4 [Sobolev VV, Denisova EV, Korsunskaya IM. Alteration of STAT3 gene expression in psoriasis treatment. Medical Council. 2020;12:71-4 (in Russian)]. DOI:10.21518/2079-701X-2020-12-71-74
36. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467-81. DOI:10.4049/jimmunol.1001426
37. Abdallah MA, Abdel-Hamid MF, Kotb AM, Mabrouk EA. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis. 2009;84:163-8. PMID: 19842576
38. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-94. DOI:10.1084/jem.20071094
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-51. DOI:10.1038/nature05505
40. Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing γδ T cells go under the skin? Nat Med. 2012;18:1748-50. DOI:10.1038/nm.3016
41. Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta. 2014;1841:463-73. DOI:10.1016/j.bbalip.2013.11.012
42. Sher T, Yi HF, McBride OW, Gonzalez FJ. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598-604. DOI:10.1021/bi00072a015
43. Sertznig P, Reichrath J. Peroxisome Proliferator-activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol. 2011;3:130-5. DOI:10.4161/derm.3.3.15025
44. Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci U S A. 2003;100:6295-6. DOI:10.1073/pnas.1232410100
45. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703-10. DOI:10.1161/01.res.0000014225.20727.8f
46. Sobolev V, Nesterova A, Soboleva A, et al. The model of PPARγ-downregulated signaling in psoriasis. PPAR Res. 2020;2020:1-11. DOI:10.1155/2020/6529057
47. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47:6-16. DOI:10.1007/s12016-013-8359-x
48. Денисова Е.В., Дениева М.И., Дворянкова Е.В., и др. К вопросу гепатотоксичности препаратов, применяемых в дерматологии. Врач. 2020;31:52-7 [Denisova EV, Denieva MI, Dvoryankova EV, et al. On hepatotoxicity of drugs used in dermatology. Vrach (Doctor). 2020;31:52-7 (in Russian)]. DOI:10.29296/25877305-2020-09-09
49. Пирузян А., Денисова Е., Дворянкова Е., и др. Комплексная патогенетическая терапия псориаза: купирование воспаления и коррекция метаболических нарушений. Врач. 2019;10:31-4 [Piruzyan A, Denisova E, Dvoryankovа E, et al. Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders. Vrach. 2019;10:30-4 (in Russian)]. DOI:10.29296/25877305-2019-10-06
50. Денисова Е., Дворянкова Е., Дениева М., и др. Обоснование применения гепатопротекторов при псориазе. Врач. 2018;9:85-8 [Denisova E, Dvoryankova E, Denieva M, et al. Rationale for the use of hepatoprotective agents in the treatment of psoriasis. Vrach. 2018;9:85-8 (in Russian)]. DOI:10.29296/25877305-2018-09-20
2. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449-53. PMID: 18609743
3. Nesterova AP, Klimov EA, Zharkova M, et al. Diseases of the skin and subcutaneous tissue. In Disease Pathways. Elsevier, 2020; p. 493-532. DOI:10.1016/B978-0-12-817086-1.00011-7
4. Nesterova AP, Yuryev A, Klimov EA, et al. Disease Pathways: An atlas of human disease signaling pathways. 1st ed. Elsevier: Waltham, 2019. DOI:10.1016/C2018-0-00586-1
5. Sobolev VV, Mezentsev AV, Ziganshin RH, et al. LC-MS/MS Analysis of Lesional and Normally Looking Psoriatic Skin Reveals Significant Changes in Protein Metabolism and RNA Processing. PLoS One. 2021;16:e0240956. DOI:10.1371/journal.pone.0240956
6. Farber EM, Nall L. The Natural History of Psoriasis in 5,600 Patients. Dermatology. 1974;148:1-18. DOI:10.1159/000251595
7. Allione A, Marcon F, Fiorito G, et al. Novel Epigenetic Changes Unveiled by Monozygotic Twins Discordant for Smoking Habits. PloS One. 2015;10:e0128265. DOI:10.1371/journal.pone.0128265
8. Park J-H, Wacholder S, Gail MH, et al. Estimation of Effect Size Distribution from Genome-Wide Association Studies and Implications for Future Discoveries. Nat Genet. 2010;42:570-5. DOI:10.1038/ng.610
9. Nair RP, Stuart PE, Nistor I, et al. Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene. Am J Hum Genet. 2006;78:827-51. DOI:10.1086/503821
10. Hız MM, Kılıç S, Oymak S, et al. Psoriasis and Genetics. IntechOpen: Rijeka, 2017. DOI:10.5772/intechopen.68344
11. De Cid R, Riveira-Munoz E, Zeeuwen PLJM, et al. Deletion of the Late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009;41:211-5. DOI:10.1038/ng.313
12. Coto-Segura P, Coto E, Mas-Vidal A, et al. Influence of Endothelial Nitric Oxide Synthase Polymorphisms in Psoriasis Risk. Arch Dermatol Res. 2011;303:445-9.
DOI:10.1007/s00403-011-1129-9
13. Fu L, Zhao Y, Lu J, et al. Functional Single Nucleotide Polymorphism-1026C/A of Inducible Nitric Oxide Synthase Gene with Increased YY1-Binding Affinity Is Associated with Hypertension in a Chinese Han Population. J Hypertens. 2009;27:991-1000. DOI:10.1097/hjh.0b013e3283294bec
14. Klimov EА, Tretiakov AV, Gapanovich ES, et al. Evaluation of the role of polymorphic variants of no-synthases genes of in pathogenesis of psoriasis. Mol Meditsina Mol Med. 2018;16. DOI:10.29296/24999490-2018-04-11
15. Klimov E, Tretiakov A, Gapanovich E, et al. Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis. J Adv Med Med Res. 2018;26:1-6. DOI:10.9734/JAMMR/2018/41039
16. Sobolev V, Sakaniya L, Tretiakov A, et al. Association of GA Genotype of SNP Rs4680 in COMT Gene with Psoriasis. Arch Dermatol Res. 2019;311:309-15. DOI:10.1007/s00403-019-01904-1
17. Sakaniya LR, Tretiakov AV, Shevtsova AA, et al. DBH gene polymorphism in psoriasis patients. Mol Meditsina Mol Med. 2019;17. DOI:10.29296/24999490-2019-04-09
18. Klimov E, Tretiakov A, Rudko O, et al. Psychodermatology: a molecular link between psoriasis and anxiety disorder. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27. DOI:10.15570/actaapa.2018.38
19. Sobolev V, Klimov E, Tretiakov A, et al. 218 polymorphism of dopamine related genes in the light of psychodermatology: association with psoriasis. J Invest Dermatol. 2017;137:S230. DOI:10.1016/j.jid.2017.07.215
20. Sobolev VV, Tret'iakov AV, Rud'ko OI, et al. Psikhodermatologiia: molekuliarnaia obshchnost' psoriaza i trevozhnogo rasstroistva. Effektivnaia farmakoterapiia. 2017;15:10-5 (in Russian).
21. Danilin IE, Niewozinska ZA, Tretiakov AV, et al. Analysis of the relationship between skin and emotional disorders in patients with psoriasis. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;11 (in Russian). DOI: 10.33920/med-01-2011-02
22. Nair RP, Duffin KC, Helms C, et al. Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-KappaB Pathways. Nat Genet. 2009;41:199-204. DOI:10.1038/ng.311
23. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE. 2011;6:e17160. DOI: 10.1371/journal.pone.0017160
24. Sobolev VV, Tret'iakov AV, Shevtsova AA, et al, Sviaz' mezhdu odnonukleotidnoi zamenoi T>C v gene MIR22 i razvitiem psoriaza. Effektivnaia farmakoterapiia. 2018;34:18-20 (in Russian).
25. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the Interleukin-17 Isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-24.
DOI:10.1111/j.1365-2133.2008.08902.x
26. Sobolev VV, Sautin ME, Piruzian ES, et al. IL-17 gene expression levels in atherosclerosis and psoriasis. Prime. 2015;5:34-8. Available at: https://www.prime-journal.com/il-17-gene-expression-levels-in-atherosclerosis-and-psoriasis/ Accessed: 13.08.2021.
27. Isailovic N, Daigo K, Mantovan A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1-11. DOI:10.1016/j.jaut.2015.04.006
28. Lai Y, Li D, Li C, et al. The Antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity. 2012;37:74-84. DOI:10.1016/j.immuni.2012.04.010
29. Sobolev VV, Denisova EV, Korsunskaia IM. Izmenenie ekspressii gena S100A8 pod vozdeistviem lazernogo izlucheniia nizkoi intensivnosti u bol'nykh psoriazom. Effektivnaia farmakoterapiia. 2021;17:14-6 (in Russian). DOI:10.33978/2307-3586-2021-17-1-14-16
30. Il'ina SA, Zolotarenko AD, Piruzian AL, et al. Ekspressiia genov S100A8 i S100A9 v porazhennoi psoriaticheskim protsessom kozhe. Tekhnologii zhivykh sistem. 2010;7:45-51 (in Russian).
31. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C Regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-66. DOI:10.1038/ni.2156
32. Kanda N, Koike S, Watanabe S. IL-17 Suppresses TNF-Alpha-Induced CCL27 Production through Induction of COX-2 in Human Keratinocytes. J Allergy Clin Immunol. 2005;116:1144-50. DOI:10.1016/j.jaci.2005.08.014
33. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-90. DOI:10.1086/511051
34. Johnson-Huang LM, Suárez-Fariñas M, Pierson KC, et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol. 2012;132:1177-87. DOI:10.1038/jid.2011.458
35. Sobolev VV, Denisova EV, Korsunskaya IM. Alteration of STAT3 gene expression in psoriasis treatment. Medical Council. 2020;12:71-4 (in Russian). DOI:10.21518/2079-701X-2020-12-71-74
36. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467-81. DOI:10.4049/jimmunol.1001426
37. Abdallah MA, Abdel-Hamid MF, Kotb AM, Mabrouk EA. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis. 2009;84:163-8. PMID: 19842576
38. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-94. DOI:10.1084/jem.20071094
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-51. DOI:10.1038/nature05505
40. Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing γδ T cells go under the skin? Nat Med. 2012;18:1748-50. DOI:10.1038/nm.3016
41. Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta. 2014;1841:463-73. DOI:10.1016/j.bbalip.2013.11.012
42. Sher T, Yi HF, McBride OW, Gonzalez FJ. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598-604. DOI:10.1021/bi00072a015
43. Sertznig P, Reichrath J. Peroxisome Proliferator-activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol. 2011;3:130-5. DOI:10.4161/derm.3.3.15025
44. Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci U S A. 2003;100:6295-6. DOI:10.1073/pnas.1232410100
45. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703-10. DOI:10.1161/01.res.0000014225.20727.8f
46. Sobolev V, Nesterova A, Soboleva A, et al. The model of PPARγ-downregulated signaling in psoriasis. PPAR Res. 2020;2020:1-11. DOI:10.1155/2020/6529057
47. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47:6-16. DOI:10.1007/s12016-013-8359-x
48. Denisova EV, Denieva MI, Dvoryankova EV, et al. On hepatotoxicity of drugs used in dermatology. Vrach (Doctor). 2020;31:52-7 (in Russian). DOI:10.29296/25877305-2020-09-09
49. Piruzyan A, Denisova E, Dvoryankovа E, et al. Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders. Vrach. 2019;10:30-4 (in Russian). DOI:10.29296/25877305-2019-10-06
50. Denisova E, Dvoryankova E, Denieva M, et al. Rationale for the use of hepatoprotective agents in the treatment of psoriasis. Vrach. 2018;9:85-8 (in Russian). DOI:10.29296/25877305-2018-09-20
2. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449-53. PMID: 18609743
3. Nesterova AP, Klimov EA, Zharkova M, et al. Diseases of the skin and subcutaneous tissue. In Disease Pathways. Elsevier, 2020; p. 493-532. DOI:10.1016/B978-0-12-817086-1.00011-7
4. Nesterova AP, Yuryev A, Klimov EA, et al. Disease Pathways: An atlas of human disease signaling pathways. 1st ed. Elsevier: Waltham, 2019. DOI:10.1016/C2018-0-00586-1
5. Sobolev VV, Mezentsev AV, Ziganshin RH, et al. LC-MS/MS Analysis of Lesional and Normally Looking Psoriatic Skin Reveals Significant Changes in Protein Metabolism and RNA Processing. PLoS One. 2021;16:e0240956. DOI:10.1371/journal.pone.0240956
6. Farber EM, Nall L. The Natural History of Psoriasis in 5,600 Patients. Dermatology. 1974;148:1-18. DOI:10.1159/000251595
7. Allione A, Marcon F, Fiorito G, et al. Novel Epigenetic Changes Unveiled by Monozygotic Twins Discordant for Smoking Habits. PloS One. 2015;10:e0128265. DOI:10.1371/journal.pone.0128265
8. Park J-H, Wacholder S, Gail MH, et al. Estimation of Effect Size Distribution from Genome-Wide Association Studies and Implications for Future Discoveries. Nat Genet. 2010;42:570-5. DOI:10.1038/ng.610
9. Nair RP, Stuart PE, Nistor I, et al. Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene. Am J Hum Genet. 2006;78:827-51. DOI:10.1086/503821
10. Hız MM, Kılıç S, Oymak S, et al. Psoriasis and Genetics. IntechOpen: Rijeka, 2017. DOI:10.5772/intechopen.68344
11. De Cid R, Riveira-Munoz E, Zeeuwen PLJM, et al. Deletion of the Late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009;41:211-5. DOI:10.1038/ng.313
12. Coto-Segura P, Coto E, Mas-Vidal A, et al. Influence of Endothelial Nitric Oxide Synthase Polymorphisms in Psoriasis Risk. Arch Dermatol Res. 2011;303:445-9.
DOI:10.1007/s00403-011-1129-9
13. Fu L, Zhao Y, Lu J, et al. Functional Single Nucleotide Polymorphism-1026C/A of Inducible Nitric Oxide Synthase Gene with Increased YY1-Binding Affinity Is Associated with Hypertension in a Chinese Han Population. J Hypertens. 2009;27:991-1000. DOI:10.1097/hjh.0b013e3283294bec
14. Klimov EА, Tretiakov AV, Gapanovich ES, et al. Evaluation of the role of polymorphic variants of no-synthases genes of in pathogenesis of psoriasis. Mol Meditsina Mol Med. 2018;16. DOI:10.29296/24999490-2018-04-11
15. Klimov E, Tretiakov A, Gapanovich E, et al. Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis. J Adv Med Med Res. 2018;26:1-6. DOI:10.9734/JAMMR/2018/41039
16. Sobolev V, Sakaniya L, Tretiakov A, et al. Association of GA Genotype of SNP Rs4680 in COMT Gene with Psoriasis. Arch Dermatol Res. 2019;311:309-15. DOI:10.1007/s00403-019-01904-1
17. Sakaniya LR, Tretiakov AV, Shevtsova AA, et al. DBH gene polymorphism in psoriasis patients. Mol Meditsina Mol Med. 2019;17. DOI:10.29296/24999490-2019-04-09
18. Klimov E, Tretiakov A, Rudko O, et al. Psychodermatology: a molecular link between psoriasis and anxiety disorder. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27. DOI:10.15570/actaapa.2018.38
19. Sobolev V, Klimov E, Tretiakov A, et al. 218 polymorphism of dopamine related genes in the light of psychodermatology: association with psoriasis. J Invest Dermatol. 2017;137:S230. DOI:10.1016/j.jid.2017.07.215
20. Соболев В.В., Третьяков А.В., Рудько О.И., и др. Психодерматология: молекулярная общность псориаза и тревожного расстройства. Эффективная фармакотерапия. 2017;15:10-5 [Sobolev VV, Tret'iakov AV, Rud'ko OI, et al. Psikhodermatologiia: molekuliarnaia obshchnost' psoriaza i trevozhnogo rasstroistva. Effektivnaia farmakoterapiia. 2017;15:10-5 (in Russian)].
21. Данилин И.Е., Невозинска З.А., Третьяков А.В., и др. Анализ взаимосвязи кожных и эмоциональных расстройств у больных псориазом. Вестник неврологии, психиатрии и нейрохирургии. 2020;11 [Danilin IE, Niewozinska ZA, Tretiakov AV, et al. Analysis of the relationship between skin and emotional disorders in patients with psoriasis. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;11 (in Russian)]. DOI: 10.33920/med-01-2011-02
22. Nair RP, Duffin KC, Helms C, et al. Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-KappaB Pathways. Nat Genet. 2009;41:199-204. DOI:10.1038/ng.311
23. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE. 2011;6:e17160. DOI: 10.1371/journal.pone.0017160
24. Соболев В.В., Третьяков А.В., Шевцова А.А., и др. Связь между однонуклеотидной заменой T>C в гене MIR22 и развитием псориаза. Эффективная фармакотерапия. 2018;34:18-20 [Sobolev VV, Tret'iakov AV, Shevtsova AA, et al, Sviaz' mezhdu odnonukleotidnoi zamenoi T>C v gene MIR22 i razvitiem psoriaza. Effektivnaia farmakoterapiia. 2018;34:18-20 (in Russian)].
25. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the Interleukin-17 Isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-24.
DOI:10.1111/j.1365-2133.2008.08902.x
26. Sobolev VV, Sautin ME, Piruzian ES, et al. IL-17 gene expression levels in atherosclerosis and psoriasis. Prime. 2015;5:34-8. Available at: https://www.prime-journal.com/il-17-gene-expression-levels-in-atherosclerosis-and-psoriasis/ Accessed: 13.08.2021.
27. Isailovic N, Daigo K, Mantovan A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1-11. DOI:10.1016/j.jaut.2015.04.006
28. Lai Y, Li D, Li C, et al. The Antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity. 2012;37:74-84. DOI:10.1016/j.immuni.2012.04.010
29. Соболев В.В., Денисова Е.В., Корсунская И.М. Изменение экспрессии гена S100А8 под воздействием лазерного излучения низкой интенсивности у больных псориазом. Эффективная фармакотерапия. 2021;17:14-6 [Sobolev VV, Denisova EV, Korsunskaia IM. Izmenenie ekspressii gena S100A8 pod vozdeistviem lazernogo izlucheniia nizkoi intensivnosti u bol'nykh psoriazom. Effektivnaia farmakoterapiia. 2021;17:14-6 (in Russian)]. DOI:10.33978/2307-3586-2021-17-1-14-16
30. Ильина С.А., Золотаренко А.Д., Пирузян А.Л., и др. Экспрессия генов S100A8 и S100A9 в пораженной псориатическим процессом коже. Технологии живых систем. 2010;7:45-51 [Il'ina SA, Zolotarenko AD, Piruzian AL, et al. Ekspressiia genov S100A8 i S100A9 v porazhennoi psoriaticheskim protsessom kozhe. Tekhnologii zhivykh sistem. 2010;7:45-51 (in Russian)].
31. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C Regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-66. DOI:10.1038/ni.2156
32. Kanda N, Koike S, Watanabe S. IL-17 Suppresses TNF-Alpha-Induced CCL27 Production through Induction of COX-2 in Human Keratinocytes. J Allergy Clin Immunol. 2005;116:1144-50. DOI:10.1016/j.jaci.2005.08.014
33. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-90. DOI:10.1086/511051
34. Johnson-Huang LM, Suárez-Fariñas M, Pierson KC, et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol. 2012;132:1177-87. DOI:10.1038/jid.2011.458
35. Соболев В.В., Денисова Е.В., Корсунская И.М. Изменение экспрессии гена STAT3 при лечении псориаза. Медицинский совет. 2020;12:71-4 [Sobolev VV, Denisova EV, Korsunskaya IM. Alteration of STAT3 gene expression in psoriasis treatment. Medical Council. 2020;12:71-4 (in Russian)]. DOI:10.21518/2079-701X-2020-12-71-74
36. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467-81. DOI:10.4049/jimmunol.1001426
37. Abdallah MA, Abdel-Hamid MF, Kotb AM, Mabrouk EA. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis. 2009;84:163-8. PMID: 19842576
38. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-94. DOI:10.1084/jem.20071094
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-51. DOI:10.1038/nature05505
40. Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing γδ T cells go under the skin? Nat Med. 2012;18:1748-50. DOI:10.1038/nm.3016
41. Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta. 2014;1841:463-73. DOI:10.1016/j.bbalip.2013.11.012
42. Sher T, Yi HF, McBride OW, Gonzalez FJ. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598-604. DOI:10.1021/bi00072a015
43. Sertznig P, Reichrath J. Peroxisome Proliferator-activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol. 2011;3:130-5. DOI:10.4161/derm.3.3.15025
44. Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci U S A. 2003;100:6295-6. DOI:10.1073/pnas.1232410100
45. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703-10. DOI:10.1161/01.res.0000014225.20727.8f
46. Sobolev V, Nesterova A, Soboleva A, et al. The model of PPARγ-downregulated signaling in psoriasis. PPAR Res. 2020;2020:1-11. DOI:10.1155/2020/6529057
47. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47:6-16. DOI:10.1007/s12016-013-8359-x
48. Денисова Е.В., Дениева М.И., Дворянкова Е.В., и др. К вопросу гепатотоксичности препаратов, применяемых в дерматологии. Врач. 2020;31:52-7 [Denisova EV, Denieva MI, Dvoryankova EV, et al. On hepatotoxicity of drugs used in dermatology. Vrach (Doctor). 2020;31:52-7 (in Russian)]. DOI:10.29296/25877305-2020-09-09
49. Пирузян А., Денисова Е., Дворянкова Е., и др. Комплексная патогенетическая терапия псориаза: купирование воспаления и коррекция метаболических нарушений. Врач. 2019;10:31-4 [Piruzyan A, Denisova E, Dvoryankovа E, et al. Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders. Vrach. 2019;10:30-4 (in Russian)]. DOI:10.29296/25877305-2019-10-06
50. Денисова Е., Дворянкова Е., Дениева М., и др. Обоснование применения гепатопротекторов при псориазе. Врач. 2018;9:85-8 [Denisova E, Dvoryankova E, Denieva M, et al. Rationale for the use of hepatoprotective agents in the treatment of psoriasis. Vrach. 2018;9:85-8 (in Russian)]. DOI:10.29296/25877305-2018-09-20
________________________________________________
2. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449-53. PMID: 18609743
3. Nesterova AP, Klimov EA, Zharkova M, et al. Diseases of the skin and subcutaneous tissue. In Disease Pathways. Elsevier, 2020; p. 493-532. DOI:10.1016/B978-0-12-817086-1.00011-7
4. Nesterova AP, Yuryev A, Klimov EA, et al. Disease Pathways: An atlas of human disease signaling pathways. 1st ed. Elsevier: Waltham, 2019. DOI:10.1016/C2018-0-00586-1
5. Sobolev VV, Mezentsev AV, Ziganshin RH, et al. LC-MS/MS Analysis of Lesional and Normally Looking Psoriatic Skin Reveals Significant Changes in Protein Metabolism and RNA Processing. PLoS One. 2021;16:e0240956. DOI:10.1371/journal.pone.0240956
6. Farber EM, Nall L. The Natural History of Psoriasis in 5,600 Patients. Dermatology. 1974;148:1-18. DOI:10.1159/000251595
7. Allione A, Marcon F, Fiorito G, et al. Novel Epigenetic Changes Unveiled by Monozygotic Twins Discordant for Smoking Habits. PloS One. 2015;10:e0128265. DOI:10.1371/journal.pone.0128265
8. Park J-H, Wacholder S, Gail MH, et al. Estimation of Effect Size Distribution from Genome-Wide Association Studies and Implications for Future Discoveries. Nat Genet. 2010;42:570-5. DOI:10.1038/ng.610
9. Nair RP, Stuart PE, Nistor I, et al. Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene. Am J Hum Genet. 2006;78:827-51. DOI:10.1086/503821
10. Hız MM, Kılıç S, Oymak S, et al. Psoriasis and Genetics. IntechOpen: Rijeka, 2017. DOI:10.5772/intechopen.68344
11. De Cid R, Riveira-Munoz E, Zeeuwen PLJM, et al. Deletion of the Late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009;41:211-5. DOI:10.1038/ng.313
12. Coto-Segura P, Coto E, Mas-Vidal A, et al. Influence of Endothelial Nitric Oxide Synthase Polymorphisms in Psoriasis Risk. Arch Dermatol Res. 2011;303:445-9.
DOI:10.1007/s00403-011-1129-9
13. Fu L, Zhao Y, Lu J, et al. Functional Single Nucleotide Polymorphism-1026C/A of Inducible Nitric Oxide Synthase Gene with Increased YY1-Binding Affinity Is Associated with Hypertension in a Chinese Han Population. J Hypertens. 2009;27:991-1000. DOI:10.1097/hjh.0b013e3283294bec
14. Klimov EА, Tretiakov AV, Gapanovich ES, et al. Evaluation of the role of polymorphic variants of no-synthases genes of in pathogenesis of psoriasis. Mol Meditsina Mol Med. 2018;16. DOI:10.29296/24999490-2018-04-11
15. Klimov E, Tretiakov A, Gapanovich E, et al. Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis. J Adv Med Med Res. 2018;26:1-6. DOI:10.9734/JAMMR/2018/41039
16. Sobolev V, Sakaniya L, Tretiakov A, et al. Association of GA Genotype of SNP Rs4680 in COMT Gene with Psoriasis. Arch Dermatol Res. 2019;311:309-15. DOI:10.1007/s00403-019-01904-1
17. Sakaniya LR, Tretiakov AV, Shevtsova AA, et al. DBH gene polymorphism in psoriasis patients. Mol Meditsina Mol Med. 2019;17. DOI:10.29296/24999490-2019-04-09
18. Klimov E, Tretiakov A, Rudko O, et al. Psychodermatology: a molecular link between psoriasis and anxiety disorder. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27. DOI:10.15570/actaapa.2018.38
19. Sobolev V, Klimov E, Tretiakov A, et al. 218 polymorphism of dopamine related genes in the light of psychodermatology: association with psoriasis. J Invest Dermatol. 2017;137:S230. DOI:10.1016/j.jid.2017.07.215
20. Sobolev VV, Tret'iakov AV, Rud'ko OI, et al. Psikhodermatologiia: molekuliarnaia obshchnost' psoriaza i trevozhnogo rasstroistva. Effektivnaia farmakoterapiia. 2017;15:10-5 (in Russian).
21. Danilin IE, Niewozinska ZA, Tretiakov AV, et al. Analysis of the relationship between skin and emotional disorders in patients with psoriasis. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;11 (in Russian). DOI: 10.33920/med-01-2011-02
22. Nair RP, Duffin KC, Helms C, et al. Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-KappaB Pathways. Nat Genet. 2009;41:199-204. DOI:10.1038/ng.311
23. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE. 2011;6:e17160. DOI: 10.1371/journal.pone.0017160
24. Sobolev VV, Tret'iakov AV, Shevtsova AA, et al, Sviaz' mezhdu odnonukleotidnoi zamenoi T>C v gene MIR22 i razvitiem psoriaza. Effektivnaia farmakoterapiia. 2018;34:18-20 (in Russian).
25. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the Interleukin-17 Isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-24.
DOI:10.1111/j.1365-2133.2008.08902.x
26. Sobolev VV, Sautin ME, Piruzian ES, et al. IL-17 gene expression levels in atherosclerosis and psoriasis. Prime. 2015;5:34-8. Available at: https://www.prime-journal.com/il-17-gene-expression-levels-in-atherosclerosis-and-psoriasis/ Accessed: 13.08.2021.
27. Isailovic N, Daigo K, Mantovan A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1-11. DOI:10.1016/j.jaut.2015.04.006
28. Lai Y, Li D, Li C, et al. The Antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity. 2012;37:74-84. DOI:10.1016/j.immuni.2012.04.010
29. Sobolev VV, Denisova EV, Korsunskaia IM. Izmenenie ekspressii gena S100A8 pod vozdeistviem lazernogo izlucheniia nizkoi intensivnosti u bol'nykh psoriazom. Effektivnaia farmakoterapiia. 2021;17:14-6 (in Russian). DOI:10.33978/2307-3586-2021-17-1-14-16
30. Il'ina SA, Zolotarenko AD, Piruzian AL, et al. Ekspressiia genov S100A8 i S100A9 v porazhennoi psoriaticheskim protsessom kozhe. Tekhnologii zhivykh sistem. 2010;7:45-51 (in Russian).
31. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C Regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-66. DOI:10.1038/ni.2156
32. Kanda N, Koike S, Watanabe S. IL-17 Suppresses TNF-Alpha-Induced CCL27 Production through Induction of COX-2 in Human Keratinocytes. J Allergy Clin Immunol. 2005;116:1144-50. DOI:10.1016/j.jaci.2005.08.014
33. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-90. DOI:10.1086/511051
34. Johnson-Huang LM, Suárez-Fariñas M, Pierson KC, et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol. 2012;132:1177-87. DOI:10.1038/jid.2011.458
35. Sobolev VV, Denisova EV, Korsunskaya IM. Alteration of STAT3 gene expression in psoriasis treatment. Medical Council. 2020;12:71-4 (in Russian). DOI:10.21518/2079-701X-2020-12-71-74
36. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467-81. DOI:10.4049/jimmunol.1001426
37. Abdallah MA, Abdel-Hamid MF, Kotb AM, Mabrouk EA. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis. 2009;84:163-8. PMID: 19842576
38. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-94. DOI:10.1084/jem.20071094
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-51. DOI:10.1038/nature05505
40. Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing γδ T cells go under the skin? Nat Med. 2012;18:1748-50. DOI:10.1038/nm.3016
41. Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta. 2014;1841:463-73. DOI:10.1016/j.bbalip.2013.11.012
42. Sher T, Yi HF, McBride OW, Gonzalez FJ. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598-604. DOI:10.1021/bi00072a015
43. Sertznig P, Reichrath J. Peroxisome Proliferator-activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol. 2011;3:130-5. DOI:10.4161/derm.3.3.15025
44. Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci U S A. 2003;100:6295-6. DOI:10.1073/pnas.1232410100
45. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90:703-10. DOI:10.1161/01.res.0000014225.20727.8f
46. Sobolev V, Nesterova A, Soboleva A, et al. The model of PPARγ-downregulated signaling in psoriasis. PPAR Res. 2020;2020:1-11. DOI:10.1155/2020/6529057
47. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47:6-16. DOI:10.1007/s12016-013-8359-x
48. Denisova EV, Denieva MI, Dvoryankova EV, et al. On hepatotoxicity of drugs used in dermatology. Vrach (Doctor). 2020;31:52-7 (in Russian). DOI:10.29296/25877305-2020-09-09
49. Piruzyan A, Denisova E, Dvoryankovа E, et al. Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders. Vrach. 2019;10:30-4 (in Russian). DOI:10.29296/25877305-2019-10-06
50. Denisova E, Dvoryankova E, Denieva M, et al. Rationale for the use of hepatoprotective agents in the treatment of psoriasis. Vrach. 2018;9:85-8 (in Russian). DOI:10.29296/25877305-2018-09-20
Авторы
О.О. Мельниченко*1, Е.В. Денисова1,2, О.В. Жукова1,3, Н.Н. Потекаев1,4
1 ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия;
3 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
4 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*dr.melnichenko@gmail.com
1 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia;
2 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia;
3 Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia;
4 Pirogov Russian National Research Medical University, Moscow, Russia
*dr.melnichenko@gmail.com
1 ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия;
3 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
4 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*dr.melnichenko@gmail.com
________________________________________________
1 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia;
2 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia;
3 Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia;
4 Pirogov Russian National Research Medical University, Moscow, Russia
*dr.melnichenko@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.